| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae47f3774e4e4f52261d7b19074f454c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68858571159db2f507e84e5d089cf39f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b8fc111ba773c3c67187e813ea92be4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04420713d8ca0e51f499cd44298a4692 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
| filingDate |
2014-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c041a42380fec2a8b6ad4be11d29469
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5710b930f504f7d234cdf4834579fd7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c18790a4e8b8dd6acf94b8e28ec0b2ec |
| publicationDate |
2014-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014288138-A1 |
| titleOfInvention |
Angiotensin II Receptor Antagonist for the Prevention or Treatment of Systemic Diseases in Cats |
| abstract |
A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10905676-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10357479-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9949954-B2 |
| priorityDate |
2006-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |